MedDevNews, Q1 2022
M&A transaction activity levels dropped for both OEMs and CMOs in Q1 2022, showing initial signs of a broader industry decline. Poor returns in the public market supported this move toward contraction, with the main remaining source of strength coming from continued elevated financing. Almost two thirds of our tracked sectors in the medical devices category witnessed lowerstock price momentum versus the S&P 500, signaling a broader market downturn. Multiple sectors still outperformed, however, including infection control & reprocessing, lab diagnostics, and ENT & respiratory.